Review of Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy Score

The PRECISE-DAPT score is a validated five-item tool (age, creatinine clearance, hemoglobin, white blood cell count, and prior bleeding) designed to estimate bleeding risk in patients on dual antiplatelet therapy (DAPT) after PCI. Derived from pooled randomized trial data, it helps identify patients at high bleeding risk (score ≥25) who may derive greater net benefit from shorter DAPT (3–6 months) versus those at lower risk suitable for standard or extended therapy. Multiple external validations demonstrate moderate discrimination (AUC/C-statistic ~0.61–0.75) across different populations types. The PRECISE-DAPT score remains a practical, evidence-based tool to aid in clinical risk-benefit evaluation for DAPT duration after PCI.